Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cholecalciferol Supplementation Did Not Change Interleukin-7 and B cell-Activating Factor Levels and CD95 Expression in B lymphocytes in Patients on Dialysis: A Randomized Pilot-Controlled Trial

Full text
Giffoni de Carvalho, Jose Tarcisio [1] ; Schneider, Marion [1] ; Cuppari, Lilian [1] ; Grabulosa, Caren Cristina [1] ; Cendoroglo, Miguel [2, 1] ; Dalboni, Maria Aparecida [1, 3]
Total Authors: 6
[1] Univ Fed Sao Paulo, UNIFESP, Div Nephrol, Sao Paulo, SP - Brazil
[2] Hosp Israelita Albert Einstein, Sao Paulo, SP - Brazil
[3] Univ Nove DeJulho UNINOVE, Postgrad Program Med, Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: JOURNAL OF RENAL NUTRITION; v. 29, n. 5, p. 454-461, SEP 2019.
Web of Science Citations: 1

Background: End-stage renal disease results in B cell lymphopenia and low levels of vitamin D. Since the link between vitamin D deficiency and B lymphocytes dysfunction are not clear in patients with end-stage renal disease, we suggest that vitamin D adequacy and factors related to the homeostasis of these cells should be investigated. B lymphocytes homeostasis is a process mainly regulated signals of grown and death as interleukin (IL)-7, B cell-activating factor (BAFF)/BAFF-receptor and CD95 expression. Objective: As vitamin D serum levels were reduced in patients with end stage renal disease and it is associated with human B homeostasis, we evaluated the effect of cholecalciferol supplementation on dialysis. Design: Randomized, double blind clinical trial in dialysis patients with 250H Vitamin D deficiency for a period of 12 weeks. Main Outcome Measure: In a pilot study, we investigated the effect of cholecalciferol supplementation (100,000 UI once per week or placebo. In vitro, peripheral blood mononuclear cells isolated by Ficoll-Hypaque centrifugation from 12 healthy volunteers were incubated with healthy or uremic serum in the presence or absence of 25 (OH)DC with 5% CO. Results: There was an increase in the serum 25(OH)D level in the cholecalciferol group. No differences were found in BAFF and IL7 levels and CD95 and BAFF-R expression in B lymphocytes from patients on dialysis after cholecalciferol supplementation. Uremic serum induced an increase in the IL-7, BAFF, BAFF-R and CD95 expression compared with the control. However, we observed no effect of incubation of 25(OH)D3 and 1,25(OH)2D3 on the expression of IL-7, BAFF, BAFF-R and CD95 when incubated in the presence of normal or uremic serum. Conclusion: Our results suggest that vitamin D is not involved in mechanisms of regulation of differentiation and survival in B lymphocytes. In conclusion, further studies are needed to explore the effects of vitamin D on B lymphocytes to better evaluate the possible impact of vitamin D on humoral response in the CKD population. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. (AU)

FAPESP's process: 12/21345-3 - Effects of cholecalciferol on modulation of expression of toll-like receptors (TLR-7 e TLR-9) and IL-6 e INF-gamma production in the b cells in uremia
Grantee:Miguel Cendoroglo Neto
Support type: Regular Research Grants
FAPESP's process: 12/19314-2 - Effect of cholecalciferol on TLR-7 and TLR-9 expression and IL-6 and INF-y production by Lymphocytes B in uremia
Grantee:José Tarcísio Giffoni de Carvalho Júnior
Support type: Scholarships in Brazil - Doctorate